A Washington State University food scientist and colleagues at Texas A&M have found that compounds in peaches can inhibit the growth of breast cancer cells and their ability to spread.
Writing in the Journal of Nutritional Biochemistry, the researchers say the compounds could be a novel addition to therapies that reduce the risk of metastasis, the primary killer in breast and many other cancers. The compounds could be given as an extract or, judging from the doses given mice in the study, two to three peaches a day.
“I would do three peaches a day,” said Giuliana Noratto, WSU assistant professor of food science.
More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus. Researchers at Inserm, the Paris Public Hospitals (AP-HP), Paris Descartes University, Paris 13 University (USPC), and Paris Diderot University have just identified the role of a new virus, hitherto unsuspected, in the occurrence of a rare type of liver cancer.
This study, based on follow-up and observation of 193 patients, is published in the 24 August issue of Nature Genetics.
Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery.
“The appropriate and precise use of IRE in appropriately selected patients with locally advanced pancreatic cancer can result in a median overall survival close to 24 months, which is nearly double the survival rate with the best new chemotherapy and chemo-radiotherapy,” said Robert Martin, M.D., Ph.D., director of surgical oncology at UofL.
High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but why it so frequently comes back after treatment has been a medical mystery.
Now a team of UCLA researchers has discovered that a subset of tumor cells that don’t produce the protein CA125, a biomarker used to test for ovarian cancer, has an enhanced ability to repair their DNA and resist programmed cell death — which allows the cells to evade the drug and live long enough to regrow the original tumor.